

Supporting Information

RHODIUM-CATALYZED OXIDATIVE OLEFINATION OF N-(2-(4,5-DIHYDROOXAZOL-2-YL)PHENYL)AMIDES WITH ARYLETHENES VIA EXTRAORDINARY N-ARYL C-H BOND FUNCTIONALIZATION

Hao Yan,^{a*} Fangpeng Hu,^b Xiaoqiang Zhou,^c Zhi Li,^a and Guosheng Huang^{b*}

^aCollege of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. of China

^bState Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. of China

^cCollege of chemistry and material, Weinan Normal University, Chaoyang Road, Weinan, 714099, P. R. of China

yanhao@sntcm.edu.cn; hgs2368@163.com

Table of Contents

1. General Remarks.	S2
2. Experimental section	S2
2.1 General procedure for the synthesis of starting materials	S2
2.1.1 Synthesis of 2-(4, 5-dihydrooxazol-2-yl)aniline	S2
2.1.2 Preparation of substrates	S2
2.2 Typical procedure for N-aryl oxidative olefination of amide tethered aryl oxazoline	S3
3. References	S3
4. Characterization data of products	S4- S12
5. ¹H NMR and ¹³C NMR spectra .	S13-S37


1. General Remarks

Products were purified by flash chromatography on 200-300 mesh silica gels. ^1H NMR and ^{13}C NMR spectra were recorded on Mercury 400 MHz in CDCl_3 using TMS as internal standard. All ^1H NMR and ^{13}C NMR chemical shifts were given as δ value (ppm) with reference to tetramethylsilane (TMS) as an internal standard. All new compounds were further characterized by HRMS. Copies of their ^1H NMR and ^{13}C NMR spectra were provided. Commercially available reagents and solvents were used without further purification.

2. Experimental section


2.1 General procedure for the synthesis of starting materials

2.1.1 Synthesis of 2-(4, 5-dihydrooxazol-2-yl)aniline^[1,2].



In a 500mL three-necked flask, 2-aminobenzonitrile (250 mmol) and ZnCl_2 (25 mmol) was added and suspended in chlorobenzene (350 mL) under nitrogen. 2-aminoethanol (45 mL, 750 mmol) was added to the suspension via a syringe. The mixture was slowly heated to reflux until no gas was produced. After refluxing for 36 h, the reaction mixture was cooled down to room temperature and the solvent was removed in a rotary evaporator. CH_2Cl_2 (250 mL) was added to the residue and washed with saturated NaHCO_3 (150 mL) and H_2O (150 mL). The aqueous fraction was extracted with CH_2Cl_2 (250 mL \times 3). The combined organic phase was dried over Na_2SO_4 , filtered and the solvent was removed in a rotary evaporator. The crude product was recrystallized from EtOAc/Hexane to give colorless crystals of the compound 2-(4,5-dihydrooxazol-2-yl)aniline.

2.1.2 Preparation of substrates^[2,3]



Acid chlorides (5 mmol) prepared from the corresponding carboxylic acid and oxalyl chloride and 2-(4,5-dihydrooxazol-2-yl)aniline (5 mmol) were added to a 50 mL flask and then dissolved with THF (10 mL). Et_3N (7.5 mmol) was taken to the vigorously stirred solution via a syringe. The reaction mixture was stirred at room temperature for 6 h and quenched with saturated $\text{NaHCO}_3 \cdot \text{H}_2\text{O}$ (100 mL) was added to the mixture and extracted with EtOAc (150 mL \times 3). Combined organic phase was washed with saturated NaCl (aq) and dried over Na_2SO_4 , and then filtered; the solvent was removed in a rotary evaporator. The crude product was recrystallized from EtOAc/Hexane to give colorless crystals of the product.


2.2 Typical procedure for N-aryl oxidative olefination of amide tethered aryl oxazoline

An oven-dried Schlenk tube was charged with N-(2-(4,5-dihydrooxazol-2-yl)phenyl)amides **1** (0.1 mmol), arylenes **2** (2.0 equiv), [RhCp*Cl₂]₂ (3 mol%), Cu(OAc)₂ (2.0 equiv), AgBF₄ (0.1 equiv), then DCE (1 mL) was added to the reaction system. The reaction was stirred at 70 °C under air for 10 h (TLC monitored). Upon completion of the reaction, cooling to room temperature, the reaction mixture diluted with ethyl acetate and washed with saturated brine. The combined organic phase was dried over anhydrous Na₂SO₄. After the solvent was evaporated in vacuo, the residues were purified by column chromatography, eluting with PET (petroleum ether)/EtOAc to afford the desired **3**.


3. References

- [1] M. Shang, S. Z. Sun, H.-X Dai, and J. Q. Yu, *J. Am. Chem. Soc.*, **2014**, 136, 3354-3357
- [2] R. Giri, N. L. Mangel, B. M. Foxman, and J. Q. Yu, *Organometallics*, **2008**, 27, 1667
- [3] I. G. Dorota, C. Grzegorz, K. W. Agata, T. Piotr, and D. Krystyna, *Eur. J. Med. Chem.* **2013**, 69, 863.


4. Characterization data of products



(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)propionamide (3a): White solid (Yield:78%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 11.11 (s, 1H), 8.52 (d, $J = 8.2$ Hz, 1H), 7.53-7.44 (m, 3H), 7.41 (d, $J = 8.2$ Hz, 1H), 7.37-7.34 (m, 3H), 7.28-7.25 (m, 1H), 6.91 (d, $J = 16.0$ Hz, 1H), 4.44 (t, $J = 9.6$ Hz, 2H), 4.15 (t, $J = 9.6$ Hz, 2H), 2.43 (q, $J = 7.6$ Hz, 2H), 1.25 (t, $J = 7.6$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.48, 164.75, 138.95, 137.42, 131.32, 130.50, 128.63, 127.70, 126.64, 121.90, 119.79, 111.77, 66.79, 54.24, 31.50, 9.63 ppm; HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 321.1603; found: 321.1608.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)butyramide(3b): White solid (Yield: 74%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 11.09 (s, 1H), 8.52 (d, $J = 8.2$ Hz, 1H), 7.53-7.47 (m, 3H), 7.41 (t, $J = 8.0$ Hz, 1H), 7.37-7.34 (m, 3H), 7.28-7.25 (m, 1H), 6.91 (d, $J = 16.0$ Hz, 1H), 4.44 (t, $J = 9.6$ Hz, 2H), 4.15 (t, $J = 9.6$ Hz, 2H), 2.37 (t, $J = 7.6$ Hz, 2H), 1.80-1.74 (m, 2H), 1.01 (t, $J = 7.4$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 171.71, 164.75, 138.95, 137.43, 131.31, 130.50, 128.64, 127.70, 126.64, 121.92, 119.84, 66.79, 54.27, 40.42, 18.96, 13.73; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 335.1760; found: 335.1763.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)isobutyramide (3c): White solid (Yield: 62%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 11.60 (s, 1H), 8.52 (d, $J = 8.4$ Hz, 1H), 7.22 (t, $J = 8.0$ Hz, 1H), 7.14-7.12 (m, 3H), 7.09-7.07 (m, 2H), 6.88 (d, $J = 8.0$ Hz, 1H), 6.83 (d, $J = 12.0$ Hz, 1H), 6.52 (d, $J = 12.0$ Hz, 1H), 4.38 (t, $J = 9.6$ Hz, 2H), 4.08 (t, $J = 9.6$ Hz, 2H), 2.62-2.55 (m, 1H), 1.29 (s, 3H), 1.27 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 175.96, 165.19, 139.70, 139.24, 136.58, 131.35, 131.17, 129.19, 128.76,


128.04, 126.94, 125.32, 119.51, 113.73, 66.64, 54.04, 37.44, 19.61 ppm; HRMS (ESI) calcd for C₂₁H₂₃N₂O₂ [M+H]⁺ : 335.1760; found: 335.1768.



(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)pivalamide (3d): White solid (Yield: 72%). ¹H NMR (400 MHz, CDCl₃): δ 11.17 (s, 1H), 8.54 (d, J = 8.2 Hz, 1H), 7.51-7.47 (m, 3H), 7.41 (t, J = 8.0 Hz, 1H), 7.37-7.33 (m, 3H), 7.28-7.24 (m, 1H), 6.91 (d, J = 16.0 Hz, 1H), 4.44 (t, J = 9.6 Hz, 2H), 4.14 (t, J = 9.6 Hz, 2H), 1.31 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 177.43, 164.66, 139.15, 138.81, 137.40, 131.24, 130.45, 128.62, 128.46, 127.69, 126.62, 121.70, 119.88, 114.05, 66.81, 54.22, 40.25, 27.61 ppm; HRMS (ESI) calcd for C₂₂H₂₅N₂O₂ [M+H]⁺ : 349.1916; found: 349.1910.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)methacrylamide (3e): White solid (Yield: 67%). ¹H NMR (400 MHz, CDCl₃): δ 11.59 (s, 1H), 8.61 (dd, J = 8.2, 1.0 Hz, 1H), 7.55-7.42 (m, 4H), 7.38-7.34 (m, 3H), 7.29-7.25 (m, 1H), 6.92 (d, J = 16.0 Hz, 1H), 5.95 (s, 1H), 5.50-5.49 (m, 1H), 4.45 (t, J = 14.4, 2H), 4.15 (t, J = 14.4, 2H), 2.08 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 166.53, 164.90, 144.48, 140.90, 139.07, 137.45, 132.00, 131.41, 130.59, 128.67, 127.74, 126.68, 122.13, 120.81, 119.81, 113.90, 104.89, 66.87, 54.23, 18.73 ppm; HRMS (ESI) calcd for C₂₁H₂₁N₂O₂ [M+H]⁺ : 333.1603; found: 333.1604.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-4-methylbenzamide (3f): White solid (Yield: 84%). ¹H NMR (400 MHz, CDCl₃): δ 12.10 (s, 1H), 8.72 (dd, J = 8.4, 0.8 Hz, 1H), 7.91 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 16.0 Hz, 1H), 7.51-7.48 (m, 3H), 7.40-7.35 (m, 3H), 7.31-7.25 (m, 3H), 6.93 (d, J = 16.0 Hz, 1H), 4.46 (t, J = 9.6 Hz, 2H), 4.19 (t, J = 9.6 Hz, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 165.54, 165.17, 142.17, 139.42, 139.18, 137.50, 132.46, 131.50, 130.59, 129.33, 128.80,

128.68, 127.74, 127.47, 126.70, 122.17, 119.95, 113.87. 66.89, 54.23, 21.49; HRMS (ESI) calcd for $C_{25}H_{23}N_2O_2$ $[M+H]^+$: 383.1760; found: 383.1763.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-4-methoxybenzamide (3g):

White solid (Yield: 68%). 1H NMR (400 MHz, $CDCl_3$): δ 12.08 (s, 1H), 8.71 (dd, $J = 8.2, 0.8$ Hz, 1H), 8.00-7.97 (m, 2H), 7.57 (d, $J = 16.0$ Hz, 1H), 7.51-7.45 (m, 3H), 7.38-7.35 (m, 3H), 7.27-7.25 (m, 1H), 7.00-6.98 (m, 2H), 6.93 (d, $J = 16.0$ Hz, 1H), 4.48 (t, $J = 9.6$ Hz, 2H), 4.20 (t, $J = 9.6$ Hz, 2H), 3.87 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 165.21, 162.38, 139.50, 139.16, 137.48, 131.49, 130.52, 129.31, 128.83, 128.67, 127.72, 127.54, 126.68, 122.06, 119.89, 113.83, 113.75, 66.87, 55.41, 54.21 ppm; HRMS (ESI) calcd for $C_{25}H_{23}N_2O_3$ $[M+H]^+$: 399.1709; found: 399.1714.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-3,5-dimethylbenzamide (3h):

White solid (Yield: 81%). 1H NMR (400 MHz, $CDCl_3$): δ 12.06 (s, 1H), 8.73 (dd, $J = 8.3, 0.8$ Hz, 1H), 7.63 (s, 2H), 7.57 (d, $J = 16.0$ Hz, 1H), 7.51-7.46 (m, 3H), 7.40-7.35 (m, 3H), 7.29-7.25 (m, 1H), 7.17 (s, 1H), 6.93 (d, $J = 16.0$ Hz, 1H), 4.47 (t, $J = 9.6$ Hz, 2H), 4.21 (t, $J = 9.6$ Hz, 2H), 2.40 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 165.88, 165.14, 139.40, 139.17, 138.22, 137.49, 135.22, 133.27, 131.52, 130.62, 128.75, 128.68, 127.74, 126.70, 125.33, 122.15, 119.89, 113.88, 66.90, 54.15, 21.35 ppm; HRMS (ESI) calcd for $C_{26}H_{25}N_2O_2$ $[M+H]^+$: 397.1916; found: 397.1914.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-3-methylbenzamide (3i): White solid (Yield: 78%). 1H NMR (400 MHz, $CDCl_3$): δ 12.13 (s, 1H), 8.74 (d, $J = 8.0$ Hz, 1H), 7.84-7.79 (m, 2H), 7.57 (d, $J = 16.0$ Hz, 1H), 7.50-7.46 (m, 3H), 7.40-7.38 (m, 2H), 7.36-7.33 (m, 3H), 7.29-7.25 (m, 1H), 6.92 (d, $J = 16.0$ Hz, 1H), 4.46 (t, $J = 9.6$, 2H), 4.19 (t, $J = 9.6$ Hz, 2H), 2.44 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 165.69,


165.14, 139.36, 139.20, 138.38, 137.47, 135.21, 132.41, 131.50, 130.61, 128.76, 128.67, 128.49, 128.31, 127.74, 126.68, 124.38, 122.22, 119.90, 113.86, 66.89, 54.16, 21.45 ppm; HRMS (ESI) calcd for C₂₅H₂₃N₂O₂ [M+H]⁺ : 383.1760; found: 383.1768.



(E)-4-chloro-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)benzamide (3j): White solid (Yield: 63%). ¹H NMR (400 MHz,) δ 12.35 (s, 1H), 8.71 (dd, J = 8.2, 0.8 Hz, 1H), 7.97-7.95 (m, 2H), 7.59 (d, J = 16.0 Hz, 1H), 7.51-7.48 (m, 3H), 7.47-7.46 (m, 1H), 7.41-7.35 (m, 3H), 7.30-7.25 (m, 1H), 6.92 (d, J = 16.0 Hz, 1H), 4.47 (t, J = 9.6 Hz, 2H), 4.18 (t, J = 9.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 164.49, 139.44, 139.28, 137.97, 137.46, 133.73, 131.62, 130.75, 128.90, 128.70, 127.80, 126.71, 122.61, 119.84, 113.66, 66.93, 54.10; HRMS (ESI) calcd for C₂₄H₂₀ClN₂O₂ [M+H]⁺ : 403.1213; found: 403.1212.




(E)-4-bromo-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)benzamide (3k): White solid (Yield: 67%). ¹H NMR (400 MHz, CDCl₃): δ 12.37 (s, 1H), 8.71 (dd, J = 8.2, 0.8 Hz, 1H), 7.90-7.88 (m, 2H), 7.85-7.57 (m, 3H), 7.51-7.47 (m, 3H), 7.41-7.35 (m, 3H), 7.30-7.26 (m, 1H), 6.92 (d, J = 16.0 Hz, 1H), 4.47 (t, J = 9.6 Hz, 2H), 4.18 (t, J = 9.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 164.59, 139.42, 139.25, 137.43, 134.17, 131.87, 131.63, 130.73, 129.08, 128.84, 128.70, 127.80, 126.71, 126.48, 122.62, 119.82, 113.63, 102.75, 66.93, 54.09 ppm; HRMS (ESI) calcd for C₂₄H₂₀BrN₂O₂ [M+H]⁺ : 447.0708; found: 447.0709.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-4-fluorobenzamide (3l): White solid (Yield: 65%). ¹H NMR (400 MHz, CDCl₃): δ 12.29 (s, 1H), 8.71 (d, J = 8.0 Hz, 1H), 8.05-8.02 (m, 2H), 7.59 (d, J = 16.0 Hz, 1H), 7.51-7.47 (m, 3H), 7.41-7.35 (m, 3H), 7.30-7.28 (m, 1H), 7.18 (t, J = 8.0 Hz, 2H), 6.93 (d, J = 16.0 Hz, 1H), 4.48 (t, J =


9.6 Hz, 2H), 4.19 (t, J = 9.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.39, 164.47, 139.39, 137.47, 131.61, 130.71, 129.88, 129.79, 128.86, 128.70, 127.79, 126.71, 122.50, 119.85, 115.78, 115.56, 113.68, 66.91, 54.14 ppm; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{20}\text{FN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 387.1509; found: 387.1506.



(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-3-(trifluoromethyl)benzamide (3m): White solid (Yield: 61%). ^1H NMR (400 MHz, CDCl_3): δ 8.79 (d, J = 8.0 Hz, 1H), 8.33 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.51-7.48 (m, 3H), 7.41-7.35 (m, 3H), 7.30-7.25 (m, 1H), 6.91 (d, J = 16.0 Hz, 1H), 4.49 (t, J = 9.6 Hz, 2H), 4.21 (t, J = 9.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.54, 163.93, 139.59, 139.32, 137.41, 136.05, 131.73, 131.16, 130.76, 129.34, 128.96, 128.69, 128.17, 127.80, 126.70, 124.22, 122.85, 119.58, 113.35, 66.97, 53.76 ppm; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 437.1477; found: 437.1472.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)-4-(trifluoromethyl)benzamide (3n): White solid (Yield: 65%). ^1H NMR (400 MHz, CDCl_3): δ 8.74 (dd, J = 8.4, 1.0 Hz, 1H), 8.14 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 16.0 Hz, 1H), 7.52-7.49 (m, 3H), 7.43-7.36 (m, 3H), 7.30-7.25 (m, 1H), 6.92 (d, J = 16.0 Hz, 1H), 4.48 (t, J = 9.6 Hz, 2H), 4.19 (t, J = 9.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.48, 164.18, 139.57, 139.18, 138.61, 137.43, 131.69, 130.85, 128.86, 128.71, 127.93, 127.84, 126.72, 125.66, 122.90, 119.83, 113.64, 66.95, 54.06 (s) ppm; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 437.1477; found: 437.1478.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)furan-2-carboxamide (3o): White solid (Yield: 67%). ^1H NMR (400 MHz, CDCl_3): δ 11.85 (s, 1H), 8.62 (dd, J = 8.0, 1.0 Hz, 1H), 7.55-7.54 (m, 1H), 7.51-7.49 (m, 3H), 7.45 (d, J = 8.0 Hz, 1H), 7.41-7.34 (m, 3H), 7.29-7.25 (m, 1H), 7.21 (dd, J = 3.6, 0.8 Hz, 1H), 6.95 (d, J = 16.0 Hz, 1H), 6.54 (dd, J = 3.6, 1.8 Hz, 1H), 4.48 (t, J = 9.6 Hz, 2H), 4.23 (t, J = 9.6 Hz, 2H);

^{13}C NMR (100 MHz, CDCl_3) δ 164.50, 156.49, 148.54, 144.49, 138.97, 138.42, 137.41, 131.36, 130.77, 128.67, 128.30, 127.78, 126.71, 122.17, 119.99, 114.87, 114.44, 112.24, 67.01, 54.38; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 359.1396; found: 359.1393.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-styrylphenyl)cyclohexanecarboxamide (3p):

White solid (Yield: 80%). ^1H NMR (400 MHz, CDCl_3) δ 11.03 (s, 1H), 8.52 (d, $J = 8.0$ Hz, 1H), 7.52-7.47 (m, 3H), 7.40 (t, $J = 8.0$ Hz, 1H), 7.37-7.33 (m, 3H), 7.28-7.24 (m, 1H), 6.91 (d, $J = 16.0$ Hz, 1H), 4.44 (t, $J = 9.6$ Hz, 2H), 4.16 (t, $J = 9.6$ Hz, 2H), 2.31-2.25 (m, 1H), 2.02-1.98 (m, 2H), 1.86-1.81 (m, 2H), 1.73-1.69 (m, 1H), 1.55-1.52 (m, 2H), 1.39-1.24 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) : δ 174.84, 164.70, 139.04, 138.87, 137.43, 131.26, 130.47, 128.62, 128.55, 127.68, 126.63, 121.78, 119.95, 113.87, 66.79, 54.29, 47.04, 29.62, 25.81, 25.73; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 375.2073; found: 375.2069.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-(4-methylstyryl)phenyl)benzamide (3q):

White solid (Yield: 70%). ^1H NMR (400 MHz, CDCl_3): δ 12.16 (s, 1H), 8.71 (d, $J = 8.0$ Hz, 1H), 8.03-8.01 (m, 2H), 7.54-7.52 (m, 2H), 7.50-7.46 (m, 3H), 7.41-7.39 (m, 3H), 7.17 (d, $J = 8.0$ Hz, 2H), 6.91 (d, $J = 16.0$ Hz, 1H), 4.45 (t, $J = 9.6$ Hz, 2H), 4.19 (t, $J = 9.6$ Hz, 2H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.50, 165.21, 139.39, 139.26, 137.70, 135.26, 134.70, 131.68, 131.48, 130.60, 129.39, 128.63, 127.73, 127.44, 126.62, 122.25, 119.76, 113.86, 66.88, 54.20, 21.25; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{23}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 383.1760; found: 383.1764..




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-(4-methoxystyryl)phenyl)benzamide (3r):

White solid (Yield: 67%). ^1H NMR (400 MHz, CDCl_3): δ 12.12 (s, 1H), 8.70 (d, $J = 7.8$ Hz, 1H), 8.03-8.01 (m, 2H), 7.55-7.52 (m, 2H), 7.50-7.48 (m, 2H), 7.46-7.42 (m, 3H), 7.39 (d, $J = 7.8$ Hz, 1H), 6.92-6.88 (m, 3H), 4.47 (t, $J = 9.6$ Hz, 2H), 4.19 (t, $J = 9.6$ Hz, 2H), 3.84 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.50, 165.25, 159.44, 139.49, 139.24, 135.29, 131.68, 131.47, 130.24, 128.64, 127.94, 127.45, 126.57, 122.12, 119.63, 114.15, 113.84, 66.90, 55.33, 54.22 ppm; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{23}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 399.1709; found: 399.1705.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-(3,5-dimethylstyryl)phenyl)benzamide (3s):

White solid (Yield: 59%). ^1H NMR (400 MHz, CDCl_3): δ 12.19 (s, 1H), 8.74 (dd, $J = 8.4, 1.0$ Hz, 1H), 8.04-8.01 (m, 2H), 7.56-7.51 (m, 2H), 7.50-7.47 (m, 2H), 7.46-7.37 (m, 3H), 7.12-7.07 (m, 2H), 7.02-7.00 (m, 1H), 4.45 (t, $J = 9.8$ Hz, 2H), 4.19 (t, $J = 9.8$ Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.51, 165.23, 139.72, 139.29, 136.28, 135.43, 135.26, 132.96, 131.68, 131.49, 130.35, 129.79, 128.73, 128.62, 128.45, 127.44, 126.33, 122.57, 119.83, 113.90, 66.89, 54.18, 21.12, 19.45 ppm; HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{25}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 397.1916; found: 397.1910.




(E)-N-(3-(3-chlorostyryl)-2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide (3t) :

White solid (Yield: 86%). ^1H NMR (400 MHz, CDCl_3): δ 12.25 (s, 1H), 8.76 (d, $J = 8.4$ Hz, 1H), 8.03-8.01 (m, 2H), 7.60-7.51 (m, 3H), 7.50-7.47 (m, 3H), 7.37-7.34 (m, 2H), 7.29 (t, $J = 7.6$ Hz, 1H), 7.25-7.23 (m, 1H), 6.84 (d, $J = 16.0$ Hz, 1H), 4.47 (t, $J = 9.6$ Hz, 2H), 4.20 (t, $J = 9.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.57, 165.02, 139.48, 139.38, 138.75, 135.20, 134.62, 131.73, 131.59, 130.36, 129.88, 129.13, 128.64, 127.62, 127.46, 126.43, 125.00, 122.38, 120.28, 113.86, 66.96, 54.20 ppm; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{20}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 403.1213; found: 403.1218.




(E)-N-(3-(4-chlorostyryl)-2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide (3u):

White solid (Yield: 67%). ^1H NMR (400 MHz, CDCl_3): δ 12.21 (s, 1H), 8.75 (d, J = 8.2 Hz, 1H), 8.03-8.01 (m, 2H), 7.57-7.51 (m, 3H), 7.50-7.47 (m, 2H), 7.43-7.40 (m, 2H), 7.38-7.32 (m, 3H), 6.87 (d, J = 16.0 Hz, 1H), 4.46 (t, J = 9.6 Hz, 2H), 4.20 (t, J = 9.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.55, 165.09, 139.44, 138.99, 135.55, 135.23, 133.54, 131.71, 131.61, 131.39, 129.85, 128.64, 127.46, 126.89, 126.73, 122.78, 120.27, 113.87, 66.91, 54.21 ppm; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{20}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 403.1213; found: 403.1215.



(E)-N-(3-(2-chlorostyryl)-2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide (3v):


White solid (Yield: 75%). ^1H NMR (400 MHz, CDCl_3): δ 12.24 (s, 1H), 8.77 (dd, J = 8.4, 1.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.66-7.63 (m, 1H), 7.59-7.51 (m, 2H), 7.50-7.48 (m, 3H), 7.43-7.38 (m, 2H), 7.32-7.25 (m, 2H), 7.23-7.20 (m, 1H), 4.46 (t, J = 9.8 Hz, 2H), 4.19 (t, J = 9.8 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.55, 165.09, 139.44, 138.99, 135.55, 135.23, 133.54, 131.71, 131.61, 131.39, 129.85, 128.64, 127.46, 126.89, 126.73, 122.78, 120.27, 113.87, 66.91, 54.21 ppm; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{20}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 403.1213; found: 403.1211.




(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-(3-fluorostyryl)phenyl)benzamide (3w):

White solid (Yield: 85%). ^1H NMR (400 MHz, CDCl_3): δ 12.24 (s, 1H), 8.76 (dd, J = 8.4, 1.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.61-7.57 (m, 1H), 7.55-7.51 (m, 2H), 7.50-7.48 (m, 2H), 7.38-7.33 (m, 1H), 7.31-7.29 (m, 1H), 7.26-7.18 (m, 2H), 6.97 (td, J = 3.4, 1.0 Hz, 1H), 6.88 (d, J = 16.0 Hz, 1H), 4.48 (t, J = 9.6 Hz, 2H), 4.20 (t, J = 9.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.58, 165.05, 164.39, 161.95, 139.90, 139.48, ,

138.77, 135.22, 131.74, 131.60, 130.22, 130.17, 130.08, 129.40, 128.65, 127.47, 122.79, 122.37, 120.28, 114.64, 114.42, 113.90, 112.94, 112.73, 66.95, 54.21 ppm; HRMS (ESI) calcd for C₂₄H₂₀FN₂O₂ [M+H]⁺ : 387.1509; found: 387.1503.







(E)-N-(3-(2-bromostyryl)-2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide (3x): White solid (Yield: 89%). ¹H NMR (400 MHz, CDCl₃): δ 12.24 (s, 1H), 8.77 (dd, J = 8.4, 1.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.64-7.58 (m, 2H), 7.55-7.48 (m, 5H), 7.43 (d, J = 7.8 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.27-7.23 (m, 1H), 7.15-7.11 (m, 1H), 4.46 (t, J = 9.6 Hz, 2H), 4.19 (t, J = 9.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 165.56, 165.10, 139.47, 138.93, 137.29, 135.24, 133.10, 131.71, 131.63, 131.58, 129.38, 128.90, 128.64, 127.53, 127.47, 126.94, 124.18, 122.83, 120.29, 113.85, 66.91, 54.21 ppm; HRMS (ESI) calcd for C₂₄H₂₀BrN₂O₂ [M+H]⁺ : 447.0708; found: 447.0704.







(E)-N-(2-(4,5-dihydrooxazol-2-yl)-3-(4-(trifluoromethyl)styryl)phenyl)benzamide (3y): White solid (Yield: 91%). ¹H NMR (400 MHz, CDCl₃): δ 12.29 (s, 1H), 8.79 (dd, J = 8.4, 1.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.67 (d, J = 16.0 Hz, 1H), 7.62-7.60 (m, 2H), 7.58-7.56 (m, 2H), 7.55-7.52 (m, 2H), 7.50-7.48 (m, 2H), 7.37 (d, J = 7.6 Hz, 1H), 6.92 (d, J = 16.0 Hz, 1H), 4.46 (t, J = 9.4 Hz, 2H), 4.20 (t, J = 9.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 165.59, 164.98, 140.95, 139.58, 138.61, 135.17, 131.76, 131.63, 131.51, 129.53, 129.32, 129.21, 129.00, 128.65, 127.46, 126.76, 125.64, 125.60, 122.42, 120.47, 113.86, 66.93, 54.19 ppm; HRMS (ESI) calcd for C₂₅H₂₀F₃N₂O₂ [M+H]⁺ : 437.1477; found: 437.1480.



5. ¹H NMR and ¹³C NMR spectra


































12.37






8.72
8.72
8.70
8.70
7.90
7.90
7.88
7.88
7.65
7.65
7.64
7.63
7.63
7.61
7.57
7.51
7.49
7.47
7.41
7.39
7.37
7.35
7.28
7.26
6.94
4.47
4.45
4.21
4.18
4.16



7.90
7.90
7.88
7.88
7.65
7.64
7.63
7.63
7.61
7.57
7.51
7.49
7.47
7.41
7.39
7.37
7.35
7.30
7.28
7.26







164.59
139.42
139.25
137.43
134.17
131.87
131.63
130.73
129.06
128.06
127.70
127.80
126.71
126.48
122.62
119.82
113.63
102.75
77.32
77.00
76.88
66.93
54.09
































-12.21

